Additional file 3 of Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice

  • Leah Katherine Cuddy (Creator)
  • Alia O. Alia (Creator)
  • Miranda A. Salvo (Creator)
  • Sidhanth Chandra (Creator)
  • Tom Grammatopoulos (Creator)
  • Craig J. Justman (Creator)
  • Peter T. Lansbury (Creator)
  • Joe Mazzulli (Creator)
  • Robert J Vassar (Creator)
  • Peter T. Lansbury (Creator)

Dataset

Description

Additional file 3: Supplementary Fig. 3. LNK-754 reduces amyloid burden and tau pathology in female and male 5XFAD mice. A Immunoblot of brain homogenates from vehicle, LNK-754 and lonafarnib treated 5XFAD mice probed for APP (6E10) and actin. Quantification of APP (B) in male (C) and female (D) mice. E Immunoblot of brain homogenates from male vehicle, LNK-754 and lonafarnib treated 5XFAD mice probed for phospho-tau (P-tau ser404) and total tau (Tau1). Quantification of phospho-tau (P-tau ser404) normalized to total tau in male and female (immunoblots shown in Fig. 1H) mice (*p = 0.012) (F). Vehicle, n = 11 (5 males, 6 females); LNK-754, n = 10 (4 males, 6 females); lonafarnib n = 10 (4 males, 6 females). Triangles represent males and circles represent females. 1-way ANOVA with Tukey’s post-hoc multiple comparisons test and 2-way ANOVA were performed.
Date made available2022
Publisherfigshare

Cite this